Last update 19.02.2021
On 29 January 2021, finding itself in a situation where the production and delivery of vaccines are still in a ramp-up phase, resulting in a temporary global shortage, the European Commission published Implementing Regulation (EU) 2021/111 making the export of certain products subject to an export authorisation.
The products for which an authorisation must be applied for in the Member State in which these products are manufactured are the following:
The authorisation must be presented when the goods are declared for export, but at the latest when the goods are released.
The export of such products is prohibited without a valid export authorisation.
No authorisation is required for exports to the following destinations:
No authorisation is required for the following transactions:
Vaccine manufacturers that have concluded advance purchase agreements shall provide to the Commission (to the following address: SANTE-PHARMACEUTICALS-B4@ec.europa.eu) and to the OCEIT (to the following address: email@example.com) the relevant data concerning their exports in the last 3 months prior to 29 January 2021, together with the first application for authorisation.
This notification must include the following information:
Failure to provide this information may result in export authorisations being refused.
The decision to grant an authorisation is subject to the condition that the volume of exports is not such that it poses a threat to the execution of advance purchase contracts concluded by the Union with vaccine manufacturers.
The applicant company will receive a decision on the granting of an export authorisation within 72 hours of the submission of a complete application. The application will be processed both by the Office for Export, Import and Transit Controls and by the European Commission within this time frame.
Biens de nature strictement civile – Vaccins contre les coronavirus du SARS – Exportation Demande d’autorisation